CIK 0001805387
CERE Cerevel Therapeutics Holdings, Inc.
Insider trading from SEC Form 4. Last filing Dec 28, 2023.
In brief
Cerevel Therapeutics Holdings, Inc. (CERE) has 22 SEC Form 4 filings on file from 14 insiders, the latest filed on Dec 28, 2023. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
19 open-market trades have been scored at CERE. The newest: Ramiro Sanchez (Chief Medical Officer) sold $425k of stock on Dec 26, 2023, filed Dec 28, 2023, scored 21 (weak), under a 10b5-1 plan. The largest of the 19 shown: Bain Capital Investors LLC (10% owner) bought $125M on Oct 16, 2023, scored 50 (moderate). 6 insiders sold within 14 days of each other around Dec 26, 2023.
10 Form 144 notices of planned sales are on file, the latest filed Dec 26, 2023.
Last 90 days
Signals
Open-market buys and sells at Cerevel Therapeutics Holdings, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 21Weak | Ramiro Sanchez Chief Medical Officer sell | $425k 10,000 shares | -41% | - | |
| 35Weak | Kenneth DiPietro Chief Human Resources Officer sell | $332k 8,000 shares | -24% | - | |
| 51Moderate | Susan ALTSCHULLER Chief Financial Officer sell | $572k 13,808 shares | -45% | - | |
| 39Weak | Scott Akamine Chief Legal Officer sell | $293k 7,072 shares | -49% | - | |
| 40Moderate | Mark Bodenrader See Remarks sell | $327k 7,889 shares | -31% | - | |
| 38Weak | Kathleen Tregoning See Remarks sell | $260k 6,288 shares | -46% | - | |
| 41Moderate | Ramiro Sanchez Chief Medical Officer sell | $421k 10,152 shares | -41% | - | |
| 33Weak | Kenneth DiPietro Chief Human Resources Officer sell | $259k 6,256 shares | -20% | - | |
| 49Moderate | Ramiro Sanchez Chief Medical Officer sell | $310k 7,500 shares | -100% | - | |
| 31Weak | Ramiro Sanchez Chief Medical Officer sell | $414k 10,000 shares | -100% | - | |
| 28Weak | Scott Akamine Chief Legal Officer sell | $676k 17,500 shares | -218% | - | |
| 27Weak | N Anthony Coles director sell | $573k 22,824 shares | -89% | - | |
| 29Weak | N Anthony Coles director sell | $680k 27,176 shares | -91% | - | |
| 33Weak | N Anthony Coles director sell | $2.5M 100,000 shares | -242% | - | |
| 30Weak | Deval L Patrick director sell | $753k 30,130 shares | -90% | - | |
| 50Moderate | Bain Capital Investors LLC owner buy | $125M 5,480,052 shares | +9% | - | |
| 58Moderate | Christopher R Gordon director, owner buy | $125M 5,480,052 shares | +9% | - | |
| 58Moderate | Adam Koppel director, owner buy | $125M 5,480,052 shares | +9% | - | |
| 58Moderate | Perceptive Advisors LLC director buy | $20M 876,808 shares | +9% | - |
Planned sales
Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales
| Filed | Seller | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Dec 26, 2023 | RAMIRO SANCHEZ Officer | 10,000 0.01% of outstanding | $425k | Dec 26, 2023 | $1.1M |
| Dec 22, 2023 | DiPietro Kenneth Officer | 8,000 0.00% of outstanding | $332k | Dec 22, 2023 | $259k |
| Dec 15, 2023 | Sanchez Ramiro Officer | 7,500 0.00% of outstanding | $310k | Dec 15, 2023 | $414k |
| Dec 7, 2023 | SCOTT AKAMINE Officer | 10,000 0.01% of outstanding | $414k | Dec 7, 2023 | $263k |
| Dec 7, 2023 | RAMIRO SANCHEZ Officer | 10,000 0.01% of outstanding | $414k | Dec 7, 2023 | none |
| Dec 5, 2023 | SCOTT AKAMINE Officer | 7,500 0.00% of outstanding | $263k | Dec 5, 2023 | none |
| Nov 7, 2023 | NEAVELLE ANTHONY COLES Director, Officer | 50,000 0.03% of outstanding | $1.2M | Nov 7, 2023 | $3.7M |
| Nov 3, 2023 | NEAVELLE ANTHONY COLES Director, Officer | 50,000 0.03% of outstanding | $1.2M | Nov 3, 2023 | $2.2M |
| Nov 2, 2023 | NEAVELLE ANTHONY COLES Director, Officer | 50,000 0.03% of outstanding | $1.3M | Nov 2, 2023 | $1.2M |
| Nov 1, 2023 | DEVAL PATRICK Director | 30,130 0.02% of outstanding | $753k | Nov 1, 2023 | none |
Transactions
The newest 50 of 66 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Dec 26, 2023 | Kathleen Tregoning See Remarks | MOption exercise Common Stock | +3,150 | $10.05 | $32k | 10,666 | Dec 28, 2023 |
| Dec 26, 2023 | Ramiro Sanchez Chief Medical Officer | MOption exercise Common Stock10b5-1 | +10,000 | $3.50 | $35k | 24,673 | Dec 28, 2023 |
| Dec 26, 2023 | Ramiro Sanchez Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -10,000 | $42.47 | $425k | 14,673 | Dec 28, 2023 |
| Dec 26, 2023 | Kathleen Tregoning See Remarks | MOption exercise Stock Option (Right to Buy)derivative | -3,150 | $0.00 | $0 | 255,082 | Dec 28, 2023 |
| Dec 26, 2023 | Ramiro Sanchez Chief Medical Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -10,000 | $0.00 | $0 | 538,435 | Dec 28, 2023 |
| Dec 22, 2023 | Kenneth DiPietro Chief Human Resources Officer | MOption exercise Common Stock | +8,000 | $3.50 | $28k | 32,663 | Dec 27, 2023 |
| Dec 22, 2023 | Kenneth DiPietro Chief Human Resources Officer | SOpen-market sale Common Stock | -8,000 | $41.45 | $332k | 24,663 | Dec 27, 2023 |
| Dec 22, 2023 | Kenneth DiPietro Chief Human Resources Officer | MOption exercise Stock Option (Right to Buy)derivative | -8,000 | $0.00 | $0 | 302,242 | Dec 27, 2023 |
| Dec 19, 2023 | Scott Akamine Chief Legal Officer | MOption exercise Common Stock | +13,796 | - | - | 14,309 | Dec 21, 2023 |
| Dec 19, 2023 | Mark Bodenrader See Remarks | MOption exercise Common Stock | +14,199 | - | - | 20,528 | Dec 21, 2023 |
| Dec 19, 2023 | Kathleen Tregoning See Remarks | MOption exercise Common Stock | +13,804 | - | - | 13,804 | Dec 21, 2023 |
| Dec 19, 2023 | Paul D. Burgess See Remarks | MOption exercise Common Stock | +23,847 | - | - | 45,727 | Dec 21, 2023 |
| Dec 19, 2023 | Ramiro Sanchez Chief Medical Officer | MOption exercise Common Stock | +24,825 | - | - | 24,825 | Dec 21, 2023 |
| Dec 19, 2023 | Susan ALTSCHULLER Chief Financial Officer | MOption exercise Common Stock | +30,721 | - | - | 30,721 | Dec 21, 2023 |
| Dec 19, 2023 | Ronald C Renaud JR President & CEO | MOption exercise Common Stock | +160,452 | - | - | 160,452 | Dec 21, 2023 |
| Dec 19, 2023 | Kenneth DiPietro Chief Human Resources Officer | MOption exercise Common Stock | +13,913 | - | - | 30,919 | Dec 21, 2023 |
| Dec 20, 2023 | Susan ALTSCHULLER Chief Financial Officer | SOpen-market sale Common Stock | -13,808 | $41.42 | $572k | 16,913 | Dec 21, 2023 |
| Dec 20, 2023 | Scott Akamine Chief Legal Officer | SOpen-market sale Common Stock | -7,072 | $41.42 | $293k | 7,237 | Dec 21, 2023 |
| Dec 19, 2023 | Mark Bodenrader See Remarks | MOption exercise Common Stock | +5,085 | - | - | 25,613 | Dec 21, 2023 |
| Dec 19, 2023 | Paul D. Burgess See Remarks | MOption exercise Restricted Stock Unitsderivative | -23,847 | $0.00 | $0 | 0 | Dec 21, 2023 |
| Dec 20, 2023 | Kathleen Tregoning See Remarks | SOpen-market sale Common Stock | -6,288 | $41.42 | $260k | 7,516 | Dec 21, 2023 |
| Dec 20, 2023 | Ramiro Sanchez Chief Medical Officer | SOpen-market sale Common Stock | -10,152 | $41.42 | $421k | 14,673 | Dec 21, 2023 |
| Dec 20, 2023 | Kenneth DiPietro Chief Human Resources Officer | SOpen-market sale Common Stock | -6,256 | $41.42 | $259k | 24,663 | Dec 21, 2023 |
| Dec 19, 2023 | Kenneth DiPietro Chief Human Resources Officer | MOption exercise Restricted Stock Unitsderivative | -13,913 | $0.00 | $0 | 0 | Dec 21, 2023 |
| Dec 19, 2023 | Susan ALTSCHULLER Chief Financial Officer | MOption exercise Restricted Stock Unitsderivative | -30,721 | $0.00 | $0 | 0 | Dec 21, 2023 |
| Dec 19, 2023 | Scott Akamine Chief Legal Officer | MOption exercise Restricted Stock Unitsderivative | -13,796 | $0.00 | $0 | 0 | Dec 21, 2023 |
| Dec 20, 2023 | Mark Bodenrader See Remarks | SOpen-market sale Common Stock | -7,889 | $41.42 | $327k | 17,724 | Dec 21, 2023 |
| Dec 19, 2023 | Kathleen Tregoning See Remarks | MOption exercise Restricted Stock Unitsderivative | -13,804 | $0.00 | $0 | 0 | Dec 21, 2023 |
| Dec 19, 2023 | Ramiro Sanchez Chief Medical Officer | MOption exercise Restricted Stock Unitsderivative | -24,825 | $0.00 | $0 | 0 | Dec 21, 2023 |
| Dec 19, 2023 | Ronald C Renaud JR President & CEO | MOption exercise Restricted Stock Unitsderivative | -160,452 | $0.00 | $0 | 0 | Dec 21, 2023 |
| Dec 19, 2023 | Mark Bodenrader See Remarks | MOption exercise Restricted Stock Unitsderivative | -14,199 | $0.00 | $0 | 0 | Dec 21, 2023 |
| Dec 19, 2023 | Mark Bodenrader See Remarks | MOption exercise Restricted Stock Unitsderivative | -5,085 | $0.00 | $0 | 0 | Dec 21, 2023 |
| Dec 15, 2023 | Ramiro Sanchez Chief Medical Officer | MOption exercise Common Stock | +7,500 | $9.88 | $74k | 7,500 | Dec 19, 2023 |
| Dec 15, 2023 | Ramiro Sanchez Chief Medical Officer | SOpen-market sale Common Stock | -7,500 | $41.39 | $310k | 0 | Dec 19, 2023 |
| Dec 15, 2023 | Ramiro Sanchez Chief Medical Officer | MOption exercise Stock Option (Right to Buy)derivative | -7,500 | $0.00 | $0 | 123,390 | Dec 19, 2023 |
| Dec 7, 2023 | Ramiro Sanchez Chief Medical Officer | MOption exercise Common Stock10b5-1 | +10,000 | $3.50 | $35k | 10,000 | Dec 11, 2023 |
| Dec 7, 2023 | Ramiro Sanchez Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -10,000 | $41.37 | $414k | 0 | Dec 11, 2023 |
| Dec 7, 2023 | Ramiro Sanchez Chief Medical Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -10,000 | $0.00 | $0 | 548,435 | Dec 11, 2023 |
| Dec 5, 2023 | Scott Akamine Chief Legal Officer | MOption exercise Common Stock10b5-1 | +7,500 | $13.17 | $99k | 8,013 | Dec 7, 2023 |
| Dec 5, 2023 | Scott Akamine Chief Legal Officer | SOpen-market sale Common Stock10b5-1 | -7,500 | $35.00 | $263k | 513 | Dec 7, 2023 |
| Dec 7, 2023 | Scott Akamine Chief Legal Officer | MOption exercise Common Stock10b5-1 | +10,000 | $13.17 | $132k | 10,513 | Dec 7, 2023 |
| Dec 7, 2023 | Scott Akamine Chief Legal Officer | SOpen-market sale Common Stock10b5-1 | -10,000 | $41.37 | $414k | 513 | Dec 7, 2023 |
| Dec 5, 2023 | Scott Akamine Chief Legal Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -7,500 | $0.00 | $0 | 264,262 | Dec 7, 2023 |
| Dec 7, 2023 | Scott Akamine Chief Legal Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -10,000 | $0.00 | $0 | 254,262 | Dec 7, 2023 |
| Nov 14, 2023 | N Anthony Coles director | MOption exercise Common Stock10b5-1 | +22,824 | $3.50 | $80k | 25,528 | Nov 16, 2023 |
| Nov 14, 2023 | N Anthony Coles director | SOpen-market sale Common Stock10b5-1 | -22,824 | $25.13 | $573k | 2,704 | Nov 16, 2023 |
| Nov 14, 2023 | N Anthony Coles director | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -22,824 | $0.00 | $0 | 2,502,417 | Nov 16, 2023 |
| Nov 7, 2023 | N Anthony Coles director | MOption exercise Common Stock10b5-1 | +27,076 | $3.50 | $95k | 29,780 | Nov 9, 2023 |
| Nov 7, 2023 | N Anthony Coles director | SOpen-market sale Common Stock10b5-1 | -27,076 | $25.02 | $678k | 2,704 | Nov 9, 2023 |
| Nov 8, 2023 | N Anthony Coles director | MOption exercise Common Stock10b5-1 | +100 | $3.50 | $350 | 2,804 | Nov 9, 2023 |
Insiders
Everyone who has filed a Form 4 here.
- Susan ALTSCHULLERChief Financial Officer
- Scott AkamineChief Legal Officer
- Bain Capital Investors LLCowner, director
- Mark BodenraderSee Remarks
- Paul D. BurgessSee Remarks
- N Anthony Colesdirector
- Kenneth DiPietroChief Human Resources Officer
- Christopher R Gordondirector, owner
- Adam Koppeldirector, owner
- Deval L Patrickdirector
- Perceptive Advisors LLCdirector, owner, other
- Ronald C Renaud JRPresident & CEO
- Ramiro SanchezChief Medical Officer
- Kathleen TregoningSee Remarks
Questions about CERE
Answered from the filings on this page, as of the latest one.
Are insiders buying CERE?
No. In the last 90 days no insider at Cerevel Therapeutics Holdings, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade CERE on the open market?
Ramiro Sanchez (Chief Medical Officer) sold $425k of CERE on Dec 26, 2023 and filed the Form 4 on Dec 28, 2023. InsiderTell scored 21 (weak), under a 10b5-1 plan, with 6 insiders on the same side within 14 days.
How many insiders file Form 4 at Cerevel Therapeutics Holdings, Inc.?
14 people have filed a Form 4 at Cerevel Therapeutics Holdings, Inc., among them Susan ALTSCHULLER (Chief Financial Officer), Scott Akamine (Chief Legal Officer), Bain Capital Investors LLC (10% owner and director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.